Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 23, 2022
Neuren submits IND & first patients complete Phase 2 trials
Dec 07, 2022
Becoming a substantial holder
Dec 02, 2022
Ceasing to be a substantial holder
Nov 23, 2022
Change in substantial holding
Oct 27, 2022
Q3 2022 quarterly activity and cash flow report
Oct 20, 2022
Neuren receives US$10 million milestone payment
Sep 14, 2022
Investor presentation, 14 September 2022
Sep 13, 2022
Rett Syndrome NDA accepted for Priority Review by FDA
Aug 24, 2022
Half-year shareholder update
Aug 24, 2022
Half Yearly Report and Accounts
1
2
3
4
Next
